quinazolines has been researched along with sulforaphane in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Herman-Antosiewicz, A; Kaczyńska, A; Świerczyńska, J | 1 |
| D'Amico, M; Lodola, A; Marchetti, C; Milelli, A; Minarini, A; Mor, M; Nicolini, B; Pruccoli, L; Simoni, E; Tarozzi, A; Ticchi, N; Tumiatti, V | 1 |
| Herman-Antosiewicz, A; Kaczyńska, A | 1 |
| Feng, X; Jiang, H; Meng, J; Meng, W; Wang, K; Zhang, F; Zhao, F | 1 |
4 other study(ies) available for quinazolines and sulforaphane
| Article | Year |
|---|---|
Sensitization of HER2 Positive Breast Cancer Cells to Lapatinib Using Plants-Derived Isothiocyanates.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Isothiocyanates; Lapatinib; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Sulfides; Sulfoxides; Thiocyanates; TOR Serine-Threonine Kinases | 2015 |
Combined inhibition of the EGFR/AKT pathways by a novel conjugate of quinazoline with isothiocyanate.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Humans; Isothiocyanates; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Sulfoxides | 2016 |
Combination of lapatinib with isothiocyanates overcomes drug resistance and inhibits migration of HER2 positive breast cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Resistance, Neoplasm; Female; Humans; Isothiocyanates; Lapatinib; Quinazolines; Receptor, ErbB-2; Signal Transduction; Sulfides; Sulfoxides; Thiocyanates | 2017 |
Sulforaphane overcomes T790M-mediated gefitinib resistance in vitro through epithelial-mesenchymal transition.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Humans; Isothiocyanates; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Sulfoxides | 2021 |